Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Craig T Jordan

Showing results (131-140 of 164) with videos related to

Pageof 17
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 31, 2014
Tyrosine kinase inhibition in leukemia induces an altered metabolic state sensitive to mitochondrial perturbationsFrancesca Alvarez-Calderon, Mark A Gregory, Catherine Pham-Danis, et al.
Oncotarget|March 13, 2015
Efficacy of a Mer and Flt3 tyrosine kinase small molecule inhibitor, UNC1666, in acute myeloid leukemiaAlisa B Lee-Sherick, Weihe Zhang, Kelly K Menachof, et al.
Blood|September 7, 2007
An orally bioavailable parthenolide analog selectively eradicates acute myelogenous leukemia stem and progenitor cellsMonica L Guzman, Randall M Rossi, Sundar Neelakantan, et al.
JCI Insight|May 10, 2016
The MERTK/FLT3 inhibitor MRX-2843 overcomes resistance-conferring FLT3 mutations in acute myeloid leukemiaKatherine A Minson, Catherine C Smith, Deborah DeRyckere, et al.
The Journal of Clinical Investigation|December 17, 2013
Therapeutic antagonists of microRNAs deplete leukemia-initiating cell activityChinavenmeni S Velu, Aditya Chaubey, James D Phelan, et al.
Plos One|August 20, 2011
Pronounced hypoxia in models of murine and human leukemia: high efficacy of hypoxia-activated prodrug PR-104Juliana Benito, Yuexi Shi, Barbara Szymanska, et al.
Nature|May 30, 2014
The sonic hedgehog factor GLI1 imparts drug resistance through inducible glucuronidationHiba Ahmad Zahreddine, Biljana Culjkovic-Kraljacic, Sarit Assouline, et al.
Eclinicalmedicine|October 27, 2025
Omacetaxine and azacitidine for untreated patients with myelodysplastic syndromes and excess blasts: a phase I/II clinical trialDaniel A Pollyea, Brett M Stevens, Diana Abbott, et al.
Cell Reports|October 30, 2025
A generalized strategy to kill leukemic cells by targeting the regulatory systems governing mitochondrial membrane potentialTing Liu, Ji-Hao Zhou, Yongbo Gong, et al.
Scientific Reports|June 4, 2024
In silico predicted compound targeting the IQGAP1-GRD domain selectively inhibits growth of human acute myeloid leukemiaDeepak M Sahasrabudhe, Jane L Liesveld, Mohammad Minhajuddin, et al.
Pageof 17

Showing results (131-140 of 164) with videos related to

Sort By:
Pageof 17
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 31, 2014
Tyrosine kinase inhibition in leukemia induces an altered metabolic state sensitive to mitochondrial perturbationsFrancesca Alvarez-Calderon, Mark A Gregory, Catherine Pham-Danis, et al.
Oncotarget|March 13, 2015
Efficacy of a Mer and Flt3 tyrosine kinase small molecule inhibitor, UNC1666, in acute myeloid leukemiaAlisa B Lee-Sherick, Weihe Zhang, Kelly K Menachof, et al.
Blood|September 7, 2007
An orally bioavailable parthenolide analog selectively eradicates acute myelogenous leukemia stem and progenitor cellsMonica L Guzman, Randall M Rossi, Sundar Neelakantan, et al.
JCI Insight|May 10, 2016
The MERTK/FLT3 inhibitor MRX-2843 overcomes resistance-conferring FLT3 mutations in acute myeloid leukemiaKatherine A Minson, Catherine C Smith, Deborah DeRyckere, et al.
The Journal of Clinical Investigation|December 17, 2013
Therapeutic antagonists of microRNAs deplete leukemia-initiating cell activityChinavenmeni S Velu, Aditya Chaubey, James D Phelan, et al.
Plos One|August 20, 2011
Pronounced hypoxia in models of murine and human leukemia: high efficacy of hypoxia-activated prodrug PR-104Juliana Benito, Yuexi Shi, Barbara Szymanska, et al.
Nature|May 30, 2014
The sonic hedgehog factor GLI1 imparts drug resistance through inducible glucuronidationHiba Ahmad Zahreddine, Biljana Culjkovic-Kraljacic, Sarit Assouline, et al.
Eclinicalmedicine|October 27, 2025
Omacetaxine and azacitidine for untreated patients with myelodysplastic syndromes and excess blasts: a phase I/II clinical trialDaniel A Pollyea, Brett M Stevens, Diana Abbott, et al.
Cell Reports|October 30, 2025
A generalized strategy to kill leukemic cells by targeting the regulatory systems governing mitochondrial membrane potentialTing Liu, Ji-Hao Zhou, Yongbo Gong, et al.
Scientific Reports|June 4, 2024
In silico predicted compound targeting the IQGAP1-GRD domain selectively inhibits growth of human acute myeloid leukemiaDeepak M Sahasrabudhe, Jane L Liesveld, Mohammad Minhajuddin, et al.
Pageof 17